Alnylam Pharmaceuticals, Inc. ALNY
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 640.51% | 327.74% | 1,228.66% | 322.56% | 362.33% |
| Total Depreciation and Amortization | 4.88% | -0.32% | -5.91% | -4.67% | -1.28% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -878.24% | 9.06% | 44.96% | -55.80% | 122.67% |
| Change in Net Operating Assets | 55.71% | -208.10% | -35.92% | 32.45% | -667.79% |
| Cash from Operations | 14.87% | 151.70% | 158.60% | 272.78% | 579.19% |
| Capital Expenditure | -475.13% | -142.64% | -143.40% | -156.12% | -189.65% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -147.13% | -158.70% | -103.02% | 68.34% | 2,069.64% |
| Cash from Investing | -162.21% | -157.08% | -122.45% | 29.76% | 1,756.55% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -80.11% | -58.68% | -73.35% | 14.95% | -28.04% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 175.51% | 175.55% | 177.89% | 1,170.82% | 27.63% |
| Cash from Financing | 104.37% | -53.35% | -65.90% | 46.20% | -508.83% |
| Foreign Exchange rate Adjustments | -35.81% | -108.89% | -150.25% | 66.99% | -106.14% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -87.71% | -103.14% | 0.03% | 224.03% | 187.07% |